Terms: = Thyroid cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC AND Treatment
15 results:
1. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary thyroid Carcinoma: A Pitfall in thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
2. NTRK fusions in solid tumours: what every pathologist needs to know.
Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA
Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis.
Vuong HG; Le HT; Le TTB; Le T; Hassell L; Kakudo K
Pathol Res Pract; 2022 Dec; 240():154180. PubMed ID: 36306725
[TBL] [Abstract] [Full Text] [Related]
4. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract] [Full Text] [Related]
5. Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric thyroid cancers.
Franco AT; Ricarte-Filho JC; Isaza A; Jones Z; Jain N; Mostoufi-Moab S; Surrey L; Laetsch TW; Li MM; DeHart JC; Reichenberger E; Taylor D; Kazahaya K; Adzick NS; Bauer AJ
J Clin Oncol; 2022 Apr; 40(10):1081-1090. PubMed ID: 35015563
[TBL] [Abstract] [Full Text] [Related]
6. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary thyroid Carcinoma.
Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract] [Full Text] [Related]
8. Mammary analog secretory carcinoma of the thyroid gland: A rare cancer harboring TRK fusion.
Huang NS; Cao YM; Lu ZW; Guan Q; Chen JY; Ma B; Chen TZ; Bai QM; Wang YL; Ji QH
Oral Oncol; 2021 Apr; 115():105092. PubMed ID: 33189578
[TBL] [Abstract] [Full Text] [Related]
9. A Case of Papillary thyroid Carcinoma and Kostmann Syndrome: A Genomic Theranostic Approach for Comprehensive treatment.
Han S; Ehrhardt J; Shukla S; Elkbuli A; Nikiforov YE; Gulec SA
Am J Case Rep; 2019 Jul; 20():1027-1034. PubMed ID: 31308356
[TBL] [Abstract] [Full Text] [Related]
10. Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma.
Kure S; Wada R; Naito Z
Med Mol Morphol; 2019 Dec; 52(4):181-186. PubMed ID: 30788603
[TBL] [Abstract] [Full Text] [Related]
11. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.
van der Tuin K; Ventayol Garcia M; Corver WE; Khalifa MN; Ruano Neto D; Corssmit EPM; Hes FJ; Links TP; Smit JWA; Plantinga TS; Kapiteijn E; van Wezel T; Morreau H
Eur J Endocrinol; 2019 Apr; 180(4):235-241. PubMed ID: 30668525
[TBL] [Abstract] [Full Text] [Related]
12. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
[TBL] [Abstract] [Full Text] [Related]
13. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract] [Full Text] [Related]
14. Pediatric, Adolescent, and Young Adult thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Characterization of Sporadic Pediatric thyroid Carcinoma with the DNA/RNA ThyroSeq v2 Next-Generation Sequencing Assay.
Picarsic JL; Buryk MA; Ozolek J; Ranganathan S; Monaco SE; Simons JP; Witchel SF; Gurtunca N; Joyce J; Zhong S; Nikiforova MN; Nikiforov YE
Pediatr Dev Pathol; 2016; 19(2):115-22. PubMed ID: 26367451
[TBL] [Abstract] [Full Text] [Related]